USO 24030
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)
Disease Types: GYN Cancer Research
Eligibility Requirements:
• Recurrent endometrial cancer (carcinoma or carcinosarcoma)
• Up to 3L prior tx for endometrial cancer including Plt-based
chemotherapy and anti-PD-(L)1 therapy separately or in combo
• Prior hormonal/hormonal-based therapy not counted as prior line
• Pts who are ineligible for anti-PD-(L)1 therapy due to medical
comorbidities not required to have prior tx with anti-PD-(L)1 agent
• Radiologically evaluable disease per RECIST v1.1 (measurable or
non-measurable)
• Documented progression during or after most recent therapy
• Tumor tissue (archival or fresh) for assessment of TROP2 and
other biomarkers
• Prior tx with TROP2-directed ADC or ADC containing
topoisomerase 1 inhibitor excluded
Available at: